QualityStocks.net News – Iomai Corp. (IOMI) Secures Agreement with Merck for Preclinical Studies

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

We would like to highlight Iomai Corp. (NASDAQ: IOMI). The company discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response.

In the Company’s news today,

Iomai Corporation (Nasdaq: IOMI) announced it has inked an agreement with Merck & Co. Inc. to conduct proof-of-principle preclinical studies regarding the company’s Iomai needle-free immunostimulant patch. Per the agreement, Merck will have the option to negotiate an exclusive license. The preclinical studies will utilize an undisclosed Merck vaccine.

“This agreement with Merck allows us to further evaluate the possible applications of our patch,” Stanley C. Erck, president and chief executive officer of Iomai, stated in the press release. “Our immunostimulant patch has the potential to improve the immune response to a wide variety of vaccines, allowing for more effective vaccines, or vaccines that work at a lower dose.”

Iomai uses TCI to administer the potent adjuvant, a skin patch that is placed over the site of the injected vaccine. The adjuvant then passes into the skin, targeting Langerhans cells, which transport the adjuvant to the lymph nodes, where it works to enhance the host’s immune response to the vaccine.

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net